GF092
TRAIL Protein, Recombinant human
Human TRAIL (TNF-Related Apoptosis Inducing Ligand), also called APO2 Ligand, is a cytotoxic protein which activates rapid apoptosis in tumor cells, but not in normal cells.
Synonym(s):
Apo2 Ligand
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
UNSPSC Code:
12352202
NACRES:
NA.75
eCl@ss:
32160405
Form:
solid
Assay:
>98% (SDS-PAGE and HPLC)
Biological source:
human
Recombinant:
expressed in E. coli
Mol wt:
19.6 kDa
biological source
human
recombinant
expressed in E. coli
assay
>98% (SDS-PAGE and HPLC)
form
solid
mol wt
19.6 kDa
manufacturer/tradename
Chemicon®
technique(s)
cell culture | mammalian: suitable
impurities
<0.1 ng/μg Endotoxin (of TRAIL/Apo2L; 1EU/μg)
input
sample type hematopoietic stem cell(s)
suitability
suitable for molecular biology
NCBI accession no.
UniProt accession no.
shipped in
dry ice
Quality Level
Gene Information
human ... TNFSF10(8743)
General description
Research area: CancerTNF-Related Apoptosis-Inducing Ligand (TRAIL) is a cytotoxic and type II membrane protein. It belongs to the tumor necrosis factor (TNF) superfamily. TRAIL is expressed by the cells of the immune system including natural killer cells, macrophages, T cells, and dendritic cells. TRAIL Protein, Recombinant human is a 19.6 kDa protein
Application
TRAIL Protein, Recombinant human has been used as anapoptosis inducer: to extract cell-free DNA (cfDNA) from various cell linesalong with BV6 to study its anticancer effects in breast cancer cell lines, tostudy its effects of ethanol-induced interferon expression on TRAIL release in neurons
Biochem/physiol Actions
TNF-Related Apoptosis-Inducing Ligand (TRAIL) promotes rapid apoptosis in tumor cells while sparing normal cells. Thisproperty of TRAIL makes it an important biotherapeutic agent in cancer therapy.It induces apoptosis by binding to two death signaling receptors, DR4 and DR5expressed on cell membranes.
Physical form
Sterile filtered, then lyophilized from 0.3 mg/mL in 10mM Sodium Phosphate + 110 mM NaCl.
Preparation Note
The lyophilized protein may be stored at room temperature for a few weeks, but is best stored at -20°C. After a quick spin, reconstitute in sterile water to a concentration of 0.5-1.0 mg/mL. This solution can be diluted into other buffered solutions and stored at 4ºC for 1 week or -20ºC for future use. Reconstituted GF092 should be stored in undiluted aliquots at -20°C for up to 6 months from date of receipt. Avoid repeated freeze/thaw cycles.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage Class
11 - Combustible Solids
wgk
WGK 3
Regulatory Listings
Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.
GF092:
jan
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Frank A E Kruyt
Cancer letters, 263(1), 14-25 (2008-03-11)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors are promising targets for the selective eradication of tumor cells while sparing normal cells. Currently, both recombinant TRAIL proteins and TRAIL receptor agonistic antibodies are being tested in the clinic, showing encouraging antitumor
The clinical trail of TRAIL
Duiker E W, et al.
European Journal of Cancer, 42(14), 2233-2240 (2006)
Hong Wang et al.
Molecular cancer therapeutics, 19(12), 2585-2597 (2020-11-18)
Complexities in treating breast cancer with bone metastasis are enhanced by a vicious protumorigenic pathology, involving a shift in skeletal homeostasis toward aggressive osteoclast activity and polarization of immune cells supporting tumor growth and immunosuppression. Recent studies signify the role
Sahar Rafat et al.
Biology, 11(11) (2022-11-12)
Cancer is the utmost common disease-causing death worldwide, characterized by uncontrollable cell division with the potential of metastasis. Overexpression of the Inhibitors of Apoptosis proteins (IAPs) and autophagy correlates with tumorigenesis, therapeutic resistance, and reoccurrence after anticancer therapies. This study
Brad A Davidson et al.
Communications biology, 7(1), 441-441 (2024-04-11)
Clinical circulating cell-free DNA (cfDNA) testing is now routine, however test accuracy remains limited. By understanding the life-cycle of cfDNA, we might identify opportunities to increase test performance. Here, we profile cfDNA release across a 24-cell line panel and utilize
Related Content
Global Trade Item Number
| SKU | GTIN |
|---|---|
| GF092 | 04053252401756 |
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service